Login · Contact

Akorn Pharmaceuticals

Akorn Investor Relations
Investor Relations
Corporate Profile

Akorn, Inc. is a specialty generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals and branded as well as private-label over-the-counter consumer health products and animal health pharmaceuticals. Akorn is an industry leader in the development, manufacturing and marketing of generic pharmaceutical products in alternate dosage forms. The Company focuses on difficult-to-manufacture sterile and non-sterile dosage forms including, but not limited to, ophthalmics, injectables, oral liquids, otics, topicals, inhalants and nasal sprays.

In order to successfully execute its strategy, Akorn continues to capitalize on its core strengths:

Research and development expertise in alternate dosage forms. The R&D efforts are primarily focused on the development of multisource generic products that are in dosage forms other than oral solid...  More >>

Stock Quote
AKRX (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Change (%) Stock is Down 0.08 (0.43%)
Data as of 03/22/18 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Notice of Waiver to Holders - 3.50% Convertible Senior Notes due June 1, 2016
Notice of Settlement Method Election - 3.50% Convertible Senior Notes Due 2016
Recent NewsMore >>
02/26/18Akorn Issues Statement on Investigation
LAKE FOREST, Ill., Feb. 26, 2018 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), a leading specialty generic pharmaceutical company, today issued the following statement: “Akorn and Fresenius Kabi AG, with the assistance of outside consultants, are investigating alleged breaches of FDA data integrity requirements relating to product development at the Company.  To date, the Company’s investigation has not found any facts that would result in a material impact on Akorn’s operations and the Co... 
Printer Friendly Version
07/19/17Akorn Shareholders Vote to Approve Merger Agreement with Fresenius Kabi
LAKE FOREST, Ill., July 19, 2017 (GLOBE NEWSWIRE) -- Akorn, Inc. (NASDAQ:AKRX), a leading specialty generic pharmaceutical company, announced that its shareholders, at a special meeting held earlier today, have overwhelmingly voted to approve the previously announced merger agreement providing for the acquisition of Akorn by Fresenius Kabi, a subsidiary of Fresenius SE & Co. KGaA (FWB:FRE). The transaction remains subject to regulatory approvals and customary closing conditions, and the... 
Printer Friendly Version
04/24/17Fresenius Kabi to Acquire Akorn
- - - - - Strategically complementary combination to enhance and diversify Fresenius Kabi’s business and portfolio - - - - - At $34.00 a share, transaction valued at approximately $4.3 billion, plus the assumption of debt - - - - - Transaction expected to close by early 2018LAKE ZURICH, Ill. and LAKE FOREST, Ill., April 24, 2017 – Fresenius Kabi has agreed to acquire Akorn (NASDAQ: AKRX), a U.S-based manufacturer and marketer of prescription and over-the-counter pharmaceutical... 
Printer Friendly Version
Latest Investor PresentationMore >>
01/09/17January 2017 Investor Presentation Download Documentation 
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Akorn, Inc. posts new information to the site. Just enter your e-mail address and click Submit.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.